{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699995385217024.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1200/jco.2014.56.7081"}},{"identifier":{"@type":"URI","@value":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2014.56.7081"}}],"dc:title":[{"@value":"Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:title>Purpose</jats:title><jats:p> Patterns of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) –negative, antihepatitis B core antigen antibody (anti-HBc) –positive patients with lymphoma receiving rituximab-containing chemotherapy have not been well described. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> HBsAg-negative, anti-HBc–positive Chinese patients with undetectable serum HBV DNA (< 10 IU/mL), diagnosed with hematologic malignancies and receiving rituximab-containing chemotherapy, were prospectively monitored every 4 weeks for up to 2 years. Entecavir was started when HBV reactivation (defined as detectable HBV DNA) was encountered. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Among 260 patients receiving rituximab-containing chemotherapy, 63 patients (24.2%) who were HBsAg negative and anti-HBc positive underwent follow-up for a median of 70 weeks (range, 6 to 104 weeks). The 2-year cumulative rate of HBV reactivation was 41.5%, occurring at a median of 23 weeks (range, 4 to 100 weeks) after rituximab treatment. The median HBV DNA level at reactivation was 43 IU/mL (range, 14 to 920 IU/mL). A baseline undetectable antibody to HBsAg (anti-HBs; < 10 mIU/mL) was the only significant risk factor that was positively associated with HBV reactivation (hazard ratio, 3.51; 95% CI, 1.37 to 8.98; P = .009). Patients with negative baseline anti-HBs, compared with those with positive anti-HBs, had a significantly higher 2-year cumulative rate of HBV reactivation (68.3% v 34.4%; P = .012). At HBV reactivation, all patients had normal ALT, and all patients but one were HBsAg negative. Entecavir successfully controlled HBV reactivation in all patients. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> A high rate of HBV reactivation was observed in HBsAg-negative, anti-HBc–positive patients undergoing rituximab-containing chemotherapy, with the risk of reactivation significantly higher in anti-HBs–negative patients. Periodic HBV DNA monitoring was an effective strategy in preventing HBV-related complications. </jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699995385217032","@type":"Researcher","foaf:name":[{"@value":"Wai-Kay Seto"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217035","@type":"Researcher","foaf:name":[{"@value":"Thomas S.Y. Chan"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217026","@type":"Researcher","foaf:name":[{"@value":"Yu-Yan Hwang"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217031","@type":"Researcher","foaf:name":[{"@value":"Danny Ka-Ho Wong"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217030","@type":"Researcher","foaf:name":[{"@value":"James Fung"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217027","@type":"Researcher","foaf:name":[{"@value":"Kevin Sze-Hang Liu"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217025","@type":"Researcher","foaf:name":[{"@value":"Harinder Gill"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217028","@type":"Researcher","foaf:name":[{"@value":"Yuk-Fai Lam"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217033","@type":"Researcher","foaf:name":[{"@value":"Albert K.W. Lie"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217034","@type":"Researcher","foaf:name":[{"@value":"Ching-Lung Lai"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217024","@type":"Researcher","foaf:name":[{"@value":"Yok-Lam Kwong"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995385217029","@type":"Researcher","foaf:name":[{"@value":"Man-Fung Yuen"}],"jpcoar:affiliationName":[{"@value":"All authors: The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0732183X"},{"@type":"EISSN","@value":"15277755"}],"prism:publicationName":[{"@value":"Journal of Clinical Oncology"}],"dc:publisher":[{"@value":"American Society of Clinical Oncology (ASCO)"}],"prism:publicationDate":"2014-11-20","prism:volume":"32","prism:number":"33","prism:startingPage":"3736","prism:endingPage":"3743"},"reviewed":"false","url":[{"@id":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2014.56.7081"}],"createdAt":"2014-10-07","modifiedAt":"2022-05-25","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360016862132723200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710502135680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all‐oral direct‐acting antivirals: Analysis of a Japanese prospective cohort"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710773454592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re‐evaluation of <scp>HB</scp>sAg seroclearance"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294740489334912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640991098880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204876526208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1390296288050770048","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390300091972855808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238061752704","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"III．B型肝炎再活性化の対策"},{"@language":"en","@value":"III. Management for reactivation of hepatitis B virus"},{"@value":"B型肝炎再活性化の対策"},{"@language":"ja-Kana","@value":"Bガタ カンエン サイカッセイカ ノ タイサク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390580295544218240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Neutralization of hepatitis B virus with vaccine-escape mutations by novel hepatitis B vaccine with large-HBs antigen"},{"@language":"ja","@value":"B型肝炎ワクチン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713049085952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390868826189491200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Delayed Hepatitis B Virus Reactivation at 33 Months after the Completion of Rituximab-based Chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1200/jco.2014.56.7081"},{"@type":"CROSSREF","@value":"10.1038/s41598-022-10665-3_references_DOI_WukS06QDOjQpUugc6ROYSopZefi"},{"@type":"CROSSREF","@value":"10.1111/hepr.12919_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.1111/liv.12980_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1587-18_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.1111/hepr.13761_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.0420-22_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.2222/jsv.72.149_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.1248/bpb.b23-00907_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5179-24_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.2169/naika.107.26_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.1016/j.leukres.2016.09.014_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.56.7468_references_DOI_YcePvnwa9oHlN7WTEoJXUrnrYF3"}]}